



**DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration**

**Office of Acquisition Management and Policy
Rockville, MD 20857-5600**

Reference: Health Resources and Services Administration 340B Prime Vendor Agreement

Solicitation No: 75R60219R00085

To Prospective Offerors:

The U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA) is soliciting offers for the 340B Prime Vendor Program in support of the distribution of covered outpatient drugs through the 340B Drug Pricing Program established by Section 340B of the Public Health Service Act (42 U.S.C. 256b, as amended).

You are invited to submit an offer in accordance with the proposal preparation instructions and evaluation factors (Attachment A) and the terms and conditions of the draft HRSA 340B Prime Vendor Agreement (Attachment B) (draft agreement). HRSA plans to enter into an agreement with the successful offeror(s) substantively similar to the draft agreement. The draft agreement identifies the anticipated terms and conditions, as well as responsibilities and requirements, of the parties to the agreement.

Questions or issues for which you require clarification or correction by the Government must be furnished electronically to rgrabill@hrsa.gov. Your questions must be received no later than 5:00 PM Eastern Standard Time (EST) on Tuesday, August 27, 2019. Questions received after the due date and time will not be considered. No Exceptions.

The Health Resources and Services Administration (HRSA) is utilizing an Electronic Proposal System (EPS). HRSA's EPS is a secure, web-based portal for the receipt of proposals. Offerors shall register in the HRSA EPS and, if they intend to submit a proposal in response to this solicitation, shall submit their proposal via the HRSA EPS.

Email, hard copy or otherwise submitted proposals will not be accepted. It is the responsibility of the offeror to ensure that its proposal is received by HRSA, in the EPS, by the designated due date and time specified in the solicitation. Allow sufficient time to register in the EPS and submit a proposal by the specified due date and time in the solicitation. It is also the responsibility of the offeror to ensure that all of the materials submitted in the EPS are complete, accurate, and in compliance with the solicitation prior to the due date and time specified for receipt of proposals.

HRSA EPS Registration Instructions/Information are located at:

<https://e-proposals.hrsa.gov/Submission/SignIn>

Once on the HRSA EPS website, click on the “HELP” icon for access to the HRSA EPS Registration Help Guide. This guide has instructions on how to register. Contact the HRSA EPS Help Desk at e-proposals@hrsa.gov for HRSA EPS technical questions after referring to the HRSA EPS Registration Help Guide. Allow up to 24-hours for a response. For any non-HRSA EPS inquiries or questions related to the solicitation, contact the Contract Specialist noted in the solicitation.

Note: A Federal Taxpayer Identification Number (TAX ID) and Dun and Bradstreet Number (DUNS) are required in order to register in the HRSA EPS.

Your proposal shall be signed by an official authorized to bind your organization and submitted to Russell Grabill via HRSA EPS no later than 5:00 PM (EST) on Tuesday, October 1, 2019.

Your proposal shall be prepared in accordance with General Instructions. This request for proposal does not commit the Government to pay any costs for the preparation and submission of a proposal nor does it commit the Government to make an award. The Government intends to make award without discussions.

Your proposal must provide a contact name and number, your company name and complete address, including street, city, county, state, zip code, e-mail address, Tax Identification Number (TIN), and Dun & Bradstreet Number (DUNS). Please note that FAR 52.204-6 Contractor Identification Number Data Universal System (DUNS Number) and 52.204-7 System for Award Management (SAM) requires any prospective awardee to have a DUNS number and be registered in the SAM database prior to award and during performance. If not registered in the SAM database within the time prescribed by the Contracting Officer, the Contracting Officer will proceed to award to the next otherwise successful registered Contractor.

If you do not have a DUNS number, please contact Dun & Bradstreet by calling 1-866-705-5711 or via the Internet at <http://www.dnb.com>. If you are not registered in the SAM, you may obtain information on registration and annual confirmation requirements via the internet at <http://www.sam.gov> or by calling 1-207-438-1690.

Any questions concerning this solicitation should be referred to Russell Grabill at rgrabill@hrsa.gov or (301) 443-1798.

Sincerely,

Donald C. Wheatley, Jr.
Contracting Officer

Proposal Preparation Instructions and Evaluation Factors for Award

I. General Instructions

1. All questions and/or inquiries concerning this solicitation must be submitted via email at rgrabill@hrsa.gov no later than 5:00 PM (EST) on Tuesday, August 27, 2019. Questions submitted after the due date will not be accepted. NO EXCEPTIONS. Any resulting addition, deletion, or change to the solicitation document will be made by issuing a formal amendment, which may be downloaded from <http://www.fbo.gov>. Offerors are instructed specifically to contact only the issuing contract office in connection with any aspect of this requirement prior to award. Communications with other HRSA personnel may result in exclusion from competition.
2. Proposals shall be printed on 8.5 x 11 inch paper, double-sided, paginated, 12 point font (Times New Roman or Arial font style only), and 1 inch margins, with a searchable PDF or MS Word format of the proposal. Each page shall be numbered and each volume shall be tabbed to correspond to the table of contents. The Offeror may include 11 x 17 inch foldouts only to display graphics, flow charts, organizational charts, or drawings. Print on graphics, flow charts, organizational charts, or drawings ONLY shall be no smaller than 10 point font (Times New Roman or Arial font style only).
3. To facilitate proposal evaluations, offerors shall structure their proposal as follows:

<u>Volume</u>	<u>Title</u>
I	Mandatory Requirements
	<ol style="list-style-type: none">1. Ability to establish a national distribution and delivery system2. Ability to establish a price negotiation system
II	Technical Requirements
	<ol style="list-style-type: none">1. Covered Outpatient Drug Distribution Services - 20 points2. 340B Drug Price Negotiation Services - 20 points3. Plan for Providing Education and Support - 20 points4. Efforts to Retain and Expand Participation - 20 points5. Organizational Experience and Capabilities - 15 points6. Value of Additional Products and Services- 5 points
III	Performance Standards
	<ol style="list-style-type: none">1. A complete Performance Standard Table can be found under section 1.9. The performance standard and method of surveillance are subject to negotiations.

4. The proposal must include a cover page with the solicitation title HRSA 340B Prime Vendor Agreement, solicitation number 75R60219R00085, the legal name of the offeror, and the point of contact of an individual legally authorized to negotiate for the offeror. Include the appropriate telephone and FAX numbers and e-mail address.
5. Offerors must submit information sufficient to evaluate their proposals based on the proposal evaluation instructions AND evaluation factors, as set forth in this solicitation. Please note that the evaluations factors for award contain additional information regarding what must be included in a proposal. Proposals must demonstrate a feasible approach to successfully implementing the requirements of this solicitation.
6. Proposals not submitted in accordance with all instructions contained in this solicitation, may result in the proposal not being considered for award.
7. The Health Resources and Services Administration (HRSA) is utilizing an Electronic Proposal System (EPS). HRSA's EPS is a secure, web-based portal for receipt of proposals. Offeror's shall register in the HRSA EPS and if they intend to submit a proposal in response to this solicitation, shall submit their proposal via the HRSA EPS.

Email, hard copy or otherwise submitted proposals will not be accepted. It is the responsibility of the offeror to ensure its proposal is received by HRSA, in the EPS, by the designated due date and time specified in the solicitation. Allow sufficient time to register in the EPS and submit a proposal by the specified due date and time in the solicitation. It is also the responsibility of the offeror to ensure that all of the material submitted in the EPS is complete, accurate, and in compliance with the solicitation prior to the due date and time specified for receipt of proposals/quotes.

HRSA EPS Registration Instructions/Information are located at:
<https://eproposals.hrsa.gov/Submission/SignIn>

Once on the HRSA EPS website, click on the "HELP" icon for access to the HRSA EPS Registration Help Guide. This guide has instructions on how to register. Contact the HRSA EPS Help Desk at eproposals@hrsa.gov for HRSA EPS technical questions after referring to the HRSA EPS Registration Help Guide. Allow up to 24-hours for a response. For any non HRSA EPS inquires or questions related to the solicitation, contact the Contract Specialist noted in the solicitation.

Note: A Federal Taxpayer Identification Number (TAX ID) and Dun and Bradstreet Number (DUNS) are required in order to register in the EPS.

8. The proposal must be signed by an official authorized to legally bind your organization and must be submitted via HRSA EPS no later than 5:00 PM (EST) on Tuesday, October 1, 2019. Late offers will not be considered for award. Submit one (1) Volume I – Mandatory Requirements, Volume II – Technical Requirements, Volume III – Performance Standards and any attachments electronically in searchable PDF or MS

Word format.

9. Offerors may propose organizational arrangements that include subcontractors, other vendors, or subsidiary agreements to provide 340B Prime Vendor Program services.

II. Evaluation Factors for Award

Offerors shall include detailed information responsive to all elements listed within the stated technical evaluation factors.

1. This solicitation has a two-phase approach. The first phase is the Mandatory Requirements Phase. Proposals will be scored on a “pass/fail” basis for each requirement and the two mandatory requirements are threshold requirements for further technical review. Proposals must receive a “pass” rating for both requirements in order to be considered further. Proposals that receive a “fail” rating for either requirement will not be eligible for award.
2. Listed below are the two Mandatory Requirements and the Technical Factors that will be used to evaluate the proposals and determine the feasibility of successful performance given the requirements of this solicitation.

A. Mandatory Qualification Criteria – Pass/Fail

The purpose of the 340B Prime Vendor is to develop, maintain and coordinate a program capable of distribution facilitation and other activities in support of the drug pricing program established by Section 340B of the Public Health Service Act (“340B Program”) that bring value to member entities and other 340B stakeholders. To that end, proposals must demonstrate that the offeror meets the following two mandatory qualifications, which will be evaluated on a pass/fail basis:

1. Demonstrate the ability to establish a national distribution and delivery system that can support operations of the 340B Program and serve all member entities as quickly as possible to limit burden on stakeholders, or have in operation such a system at the time of award.
2. Demonstrate the ability to establish a price negotiation system that allows for the negotiation of sub-ceiling prices which will benefit all member entities as quickly as possible to limit burden on stakeholders, or have such a system in operation at the time of award.

B. Technical Evaluation Criteria

HRSA will evaluate offers which receive a “pass” rating for both mandatory evaluation criteria against the technical evaluation criteria below. Proposals will be evaluated for the degree to which they demonstrate detailed information responsive to each of the technical evaluation factors.

1. Covered Outpatient Drug (340B drug) Distribution Services 20 points

Offeror's proposal shall include and demonstrate:

- a. Ability to provide efficient 340B drug distribution services for all member entities at the lowest possible costs that support 340B Program compliance;
- b. Ease of access to 340B drug distribution services, especially for small health care providers;
- c. Access to standard industry reports on drug purchases and inventory management specific to the 340B Program;
- d. Access to optional services and catalog items; and
- e. Appropriateness of proposed performance standards for 340B drug distribution.

2. 340B Drug Price Negotiation Services 20 points

Offeror's proposal shall include and demonstrate:

- a. Capacity to conduct timely and successful 340B price negotiations with all types of drug manufacturers to support 340B Program compliance;
- b. Ability to collect data about the 340B purchasing patterns and future needs of covered entities while maintaining appropriate confidentiality to protect the competitive positions of all manufacturers, distributors and member entities;
- c. Appropriateness of proposed performance standards for 340B pricing integrity, negotiation and data confidentiality; and
- d. Plan for conducting negotiations to obtain discounts on 340B drugs that are lower than 340B statutory ceiling prices (i.e., sub-ceiling prices) for member entities.

3. Plan for Providing Education and Support 20 points

Offeror's proposal shall include and demonstrate:

- a. Ability to maximize resources to improve services and value to 340B Program operations and program integrity, including information technology, and training to ensure compliance with applicable 340B Program policies and requirements as well as applicable HHS policy and requirements; and

- b. Plan for education and to provide technical assistance and training in alignment with 340B requirements.
- c. Methodology of providing periodic quarterly reports to member entities and data accessible online.

4. Efforts to Retain and Expand Participation 20 points

Offeror's Proposal shall include and demonstrate:

- a. Plan for retaining the member entities and their current distributors and increasing the participation of covered entities in the 340B Prime Vendor Program;
- b. Commitment to excellent customer support;
- c. Plan for establishing a customer consultation group(s) made up of selected representative member entities and organizations which support and promote the interests of covered entities to assist in the implementation of the 340B Prime Vendor Program;
- d. Proposed performance standards for covered entity enrollment, 340B distribution services, 340B drug price negotiation, stakeholder education and support, data confidentiality, inclusion of other optional services and catalog items, and reports to HRSA; and
- e. Ability to handle rapid expansion of services. This should include a description of all planned sub-contractual relationships with other vendors and partners, including the dates they have been or are planned to be effective and operational.

5. Organizational Experience and Capabilities 15 points

Offeror's Proposal shall include and demonstrate:

- a. Experience and qualifications of key personnel proposed to perform the 340B Prime Vendor work. Key personnel are defined as senior staff, and any other staff with critical knowledge, skills and abilities integral to the Prime Vendor work and performance of the Agreement. Experience and qualifications shall include a curriculum vitae/resume of the offeror's proposed key personnel;
- b. Experience in providing nation-wide drug distribution and negotiation services as specified under Technical Factors 1 and 2, above;
- c. Organizational structure, mechanism to service geographically dispersed entities through use of partnerships and other vendors, and mechanism to

effectively negotiate 340B prices with large numbers of manufacturers;

- d. Ability to address how value to the government will be maximized by working with other parties, organizations, and/or vendors to enhance the capabilities and functions of the 340B Prime Vendor; and
- e. A general description of the overall business model, financial capabilities and pricing approach that will be utilized to ensure the financial viability and sustainability of the 340B Prime Vendor Program.
- f. In the case of a proposal that involves the participation of two or more organizations (including subcontractors) or vendors, offeror shall include letters of intent which describe the relationship among the participants, including the ability of the lead organization (the offeror) to manage 340B Prime Vendor Program operations as a whole. If the proposal envisions the participation of other organizations or vendors in the future, it must address how they will be engaged and function within the overall proposal.
- g. If the offeror proposes that some of the services provided as part of this draft agreement will be performed by someone other than the offeror's staff, then the offeror shall submit a risk mitigation plan so that HRSA can evaluate the risk associated with the subcontracting arrangements to ensure successful contract performance and how the offeror would manage these subcontracting arrangements as an efficient entity.

6. Value of Additional Products and Services

5 points

Offeror's proposal shall include and demonstrate:

- a. How it will offer lower cost products and services utilized by member entities other than covered outpatient drugs (e.g. vaccines, prescription vials, etc.); and
- b. Proposed activities and services that bring additional value to 340B participants and the Government that support 340B Program compliance.
- c. A summary and a strategic plan for the proposed activities, including a description of the level of support to the 340B Program.

Prime Vendor Solicitation Questions and Answers

Question 1:

Specifically regarding Section 5 entitled “Term and Termination”, would HRSA consider modifying Section 5 of the Draft Agreement to either a straight five (5) year base contract term or at least a three (3) year base contract term with one (1) two-year renewal option? Our rationale for modifying the terms of the agreement include:

- a) Since the first 340B Prime Vendor agreement award in 1999, the agreement has never been awarded for a base period of less than 3 years.
- b) HRSA has no year to year funding requirement with the 340B Prime Vendor agreement as the awarded vendor must develop its own funding source. A longer term agreement will reduce the administrative burden on HRSA.
- c) Based on our previous experience, over 125 agreements will need to be established and maintained to support a successful 340B Prime Vendor model. It is unlikely any vendor can accomplish such a task working under the proposed 12 month contract term with annual renewals. It is an industry standard with pharmaceutical manufacturers and wholesalers to contract for 3 year or longer terms. It is also a tremendous expenditure of time and money to execute a contract with a 12 month term.
- d) Without a longer term agreement, HRSA’s 340B Prime Vendor will risk subjecting member entities to price instability and potential price increases each year of the agreement.

I hope HRSA will agree that a longer term agreement is important in driving greater program value and stability for HRSA and the member entities, while providing the appropriate incentives for pharmaceutical manufacturers and wholesalers to engage the program with best market pricing.

Government Response 1:

The Government has revised Attachment B, Section 5. Term and Termination from “a base period of 12 months with four (4) 12 month option periods” to “a three (3) year base period, followed by two (2) three (3) year option periods and one (1) one (1) year option period. See Solicitation Amendment 0001.

Question 2:

What is the statutory or regulatory citation for requiring that the 340B Prime Vendor provide education and support to 340B covered entities as outlined in section three of the Technical Evaluation Criteria?

Government Response 2:

The Government intends to enter into the 340B Prime Vendor Agreement under the authority of Section 340B(a)(8) of the Public Health Service Act.

Question 3:

- a) What is the current format, content, and frequency with which the current 340B Prime Vendor (the incumbent) provides education and support to 340B covered entities?
- b) Can HRSA provide a specific example of educational programming offered by the incumbent?
- c) Can HRSA provide a minimal acceptable standard for the format, content, and frequency with which education and support to 340B covered entities must be provided?

Government Response 3:

The Government does not comment on performance of the incumbent or work performed under the current Prime Vendor agreement. However, the following website is available to the general public and may contain useful information: <https://apexus.com/340b-prime-vendor-program>. Each vendor may propose the format, content, and frequency with which education and support to 340B covered entities will be provided, based upon their proposed approach to meeting this requirement.

Offers are currently being solicited for the 340B Prime Vendor Program, which is a competitive procedure, as detailed in the Solicitation No: 75R60219R00085.

The solicitation can be found at:

<https://www.fbo.gov/notices/a87131c908ecce4ae73f5ab5cb02f7a5>

Question 4:

What is the statutory or regulatory citation for requiring that the 340B Prime Vendor provide efforts to retain and expand participation in the 340B Prime Vendor Program as outlined in section four of the Technical Evaluation Criteria?

Government Response 4:

The Government intends to enter into the 340B Prime Vendor Agreement under the authority of Section 340B(a)(8) of the Public Health Service Act.

Question 5:

- a) How does the incumbent provide efforts to retain and expand participation in the 340B Prime Vendor Program?
- b) Can HRSA provide a specific example of efforts to retain and expand participation performed by the incumbent?

c) Can HRSA provide details regarding expectations for retainment percentages and expansion goals?

Government Response 5:

The Government does not comment on performance of the incumbent or work performed under the current Prime Vendor agreement. However, the following website is available to the general public and may contain useful information: <https://apexus.com/340b-prime-vendor-program>. Each vendor may propose efforts to retain and expand participation in the 340B Prime Vendor Program, based upon their proposed approach to meeting this requirement.

Question 6:

a) What is the current composition of the incumbent's customer consultation group(s) and what is the frequency with which they meet?

b) Can HRSA provide details regarding expectations for composition of customer consultation group(s) and the frequency with which they should meet?

Government Response 6:

The Government does not comment on performance of the incumbent or work performed under the current Prime Vendor agreement. Consultant groups are currently convened by covered entity type to understand their needs; however, expectations for composition of customer consultation group(s) and the frequency with which they should meet may be proposed by the offeror, based on their proposed approach to meeting this requirement.

Question 7:

What is the statutory or regulatory citation for requiring that the 340B Prime Vendor include and demonstrate the value of additional products and services, that are not covered outpatient drugs, as outlined in section six of the Technical Evaluation Criteria?

Government Response 7:

The Government intends to enter into the 340B Prime Vendor Agreement under the authority of Section 340B(a)(8) of the Public Health Service Act.

Question 8:

a) How does the incumbent offer lower cost products and services other than with respect to covered outpatient drugs?

b) Can HRSA provide a specific example where the incumbent offered lower cost products that were not covered outpatient drugs for 340B covered entities?

c) Can HRSA provide details regarding expectations for the number and type of offerings for non-outpatient covered drugs?

Government Response 8:

The Government does not comment on performance of the incumbent or work performed under the current Prime Vendor agreement. However, the following website is available to the general public and may contain useful information: <https://apexus.com/340b-prime-vendor-program>. Expectations for the number and type of offerings for non-outpatient covered drugs may be proposed by the offeror, based on their proposed approach to meeting this requirement.

Question 9:

- a) How does the incumbent bring additional value to 340B covered entities and the Government that support 340B Program compliance?

- b) Can HRSA provide a specific example of how the incumbent has provided additional value to 340B covered entities and the Government?

- c) Can HRSA provide details regarding expectations for how value to 340B covered entities and the Government will be quantified?

Government Response 9:

The Government does not comment on performance of the incumbent or work performed under the current Prime Vendor agreement. However, the following website is available to the general public and may contain useful information: <https://apexus.com/340b-prime-vendor-program>. It is the Offeror's responsibility to propose how it will bring value to 340B covered entities and to the Government. The Government will evaluate each proposal using the stated evaluation factors listed in the solicitation.

Question 10:

- a) What is the current business model of the incumbent and annual revenue to assist in assessing the potential revenue prior to responding to the solicitation?

- b) What percentage of total revenue is attributed to various revenue inputs such as administrative fees from manufacturers, fees from wholesale distributors from the WAC/sub-WAC account, 340B account, and wholesaler generic source contracts subcontracted through the Prime Vendor, as well as any other fees?

Government Response 10:

This is proprietary information of the incumbent.

Question 11:

- a) To what extent is the 340B Prime Vendor's income and expenses, and the source of its income and expenses, transparent to HRSA and the general public?

- b) Will HRSA audit the 340B Prime Vendor's revenue and expenses?

c) If so, will this information be made available to the public?

d) What transparency standards does HRSA currently apply to the incumbent?

Government Response 11:

The Government does not audit revenue, income or expenses. Per Section 6. Retention of Records and Auditing, of the Draft Agreement, the Government may examine or audit purchase transactions for member entities and work papers developed for price negotiations. Additionally, the Government does monitor performance via the receipt of reports, as detailed in Section 1.7 Reports, of the Draft Agreement.

Question 12:

I would like to know if this was competitively bid, based on what and other small questions about this solicitation.

Government Response 12:

The current agreement was awarded competitively. A solicitation was posted to Federal Business Opportunities website in 2014 requesting interested parties from industry to submit proposals to be considered for award of the 340B Prime Vendor.

Question 13:

I have downloaded the solicitation and the attachment. Needed are the bid tabulation, the evaluation sheet and the award letter.

Government Response 13:

These documents are not solicitation attachments and may be created after proposals have been submitted and received by the Government. They typically contain source selection information and offerors' confidential information, and are not publicly available.

Question 14:

This program has been awarded to a prime vendor, is that current contract with Apexus about to expire? Or can you guide me to the correct person to talk to.

Government Response 14:

The current prime vendor agreement ends December 30, 2019.

Question 15:

I am actually interested in obtaining copy of the evaluation and the award letter.

Government Response 15:

These documents are not solicitation attachments and may be created after proposals have been submitted and received by the Government. They typically contain source selection information and offerors' confidential information, and are not publicly available.

Question 16:

Whom can I speak to from the agency to provide me more information on the current contract with Apexus?

Government Response 16:

You may submit your inquiry about a current contract at the HRSA FOIA website at:
<https://www.hrsa.gov/foia/index.html>



**DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration**

**Office of Acquisition Management and Policy
Rockville, MD 20857-5600**

Reference: Health Resources and Services Administration 340B Prime Vendor Agreement

Solicitation No: 75R60219R00085 Amendment 0001

To Prospective Offerors:

The U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA) is issuing Amendment 0001 to solicitation 75R60219R00085. The purpose of this amendment is to revise the term of the 340B Prime Vendor Agreement following questions that were received regarding solicitation 75R60219R00085. Additionally, the numbering sequence of Sections 1.1.1 through 1.1.6 of Attachment B Agreement/SOW has been modified to correct typographical errors in the numbering.

Attachment A and the proposal due date and time of the solicitation remain unchanged.

Questions concerning this solicitation should be referred to Russell Grabill at rgrabill@hrsa.gov or (301) 443-1798.

Sincerely,

Donald C. Wheatley, Jr.
Contracting Officer

Attachments:
Prime Vendor Solicitation Questions and Answers
Attachment B Agreement/SOW



**DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration**

**Office of Acquisition Management and Policy
Rockville, MD 20857-5600**

Reference: Health Resources and Services Administration 340B Prime Vendor Agreement

Solicitation No: 75R60219R00085 Amendment 0002

To Prospective Offerors:

The U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA) is issuing Amendment 0002 to solicitation 75R60219R00085. The purpose of this amendment is to remind prospective offerors that the closing date and time of solicitation 75R60219R00085 is no later than 5:00 PM (EST) on TUESDAY, OCTOBER 1, 2019 and that the HRSA is utilizing an Electronic Proposal System (EPS) to receive proposals.

HRSA's EPS is a secure, web-based portal for the receipt of proposals. Offerors shall register in the HRSA EPS and, if they intend to submit a proposal in response to this solicitation, shall submit their proposal via the HRSA EPS.

It is the responsibility of the offeror to ensure that its proposal is received by HRSA, in the EPS, by the designated due date and time specified in the solicitation. Allow sufficient time to register in the EPS and submit a proposal by the specified due date and time in the solicitation. It is also the responsibility of the offeror to ensure that all of the materials submitted in the EPS are complete, accurate, and in compliance with the solicitation prior to the due date and time specified for receipt of proposals.

HRSA EPS Registration Instructions/Information are located at:

<https://eproposals.hrsa.gov/Submission/SignIn>

Once on the HRSA EPS website, click on the "HELP" icon for access to the HRSA EPS Registration Help Guide. This guide has instructions on how to register. Contact the HRSA EPS Help Desk at eproposals@hrsa.gov for HRSA EPS technical questions after referring to the HRSA EPS Registration Help Guide. Allow up to 24-hours for a response. For any non-HRSA EPS inquiries or questions related to the solicitation, contact the Contract Specialist noted in the solicitation.

Note: A Federal Taxpayer Identification Number (TAX ID) and Dun and Bradstreet Number (DUNS) are required in order to register in the HRSA EPS.

Solicitation Number: 75R60219R00085

Questions concerning this solicitation should be referred to Russell Grabill at rgrabill@hrsa.gov or (301) 443-1798.



**DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration**

**Office of Acquisition Management and Policy
Rockville, MD 20857-5600**

Reference: Health Resources and Services Administration 340B Prime Vendor Agreement

Solicitation No: 75R60219R00085 Amendment 0003

To Prospective Offerors:

The U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA) is issuing Amendment 0003 to solicitation 75R60219R00085.

Due to a system issue, the Electronic Proposal System (EPS) currently does not accept "\$0.00" as a valid entry for Offeror's price, i.e. "Base Price." Because this system issue cannot be resolved before October 1, 2019, Offerors are instructed to insert "1.00" in the field entitled "Base Price." This will allow Offerors' proposals to be submitted via the EPS. The Government understands that "1.00" is being used for this field, per the Government's direction, due to a technical issue related to EPS. This will not be deemed to conflict with each Offeror's proposal, and no proposal will be considered unacceptable due to the use of "1.00" in this field.

Questions concerning this solicitation should be referred to Russell Grabill at rgrabill@hrsa.gov or (301) 443-1798.

HRSA 340B Prime Vendor Agreement

Response to Solicitation No.

75R60219R00085

Revised Proposal

Apexus, LLC

Christopher Hatwig

President

Phone: (469) 299-7301

FAX: (469) 299-7290

Email: Chris.Hatwig@Apexus.com

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4), (b) (6)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4)

(b) (4), (b) (6)

(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)



(b) (4), (b) (6)